Skip to content

Study · Animal study (in vivo) · rat · 2006

3 results

[Protective effect of peptide semax the rat heart in acute myocardial infarction].

Golubeva AV, Gavrilova SA, Lipina TV, Shornikova MV, Postnikov AB, Andreeva LA, Chentsov IuS, Koshelev VB

Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova1 Jun 2006

PMID16967870 (opens in a new tab)PepBankPUB-16967870
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute myocardial infarction, semax had no effect on cardiac function.

    In plain wordsIn rats with a heart attack, semax did not change how well the heart worked.

    Peptide
    Semax
    Outcome
    No significant changeCardiac function
    Study

    ratn: not reported in source

    Acute myocardial infarction by left coronary artery occlusion
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    150 microg/kg · intraperitoneal · two doses, 15 min and 2 hours after coronary occlusionAs given in this study (rat).

    Source sentences

    Summary
    Semax (150 microg/kg), given i. p. 15 min and 2 hours after coronary occlusion, caused no effect on cardiac function, but completely prevented ischemia-induced ultrastructural changes of cardiomyocytes.
    1 context sentence
    Summary · context
    AMI was induced by left coronary artery occlusion, myocardial ischemic area averaged 30 % of left ventricle.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute myocardial infarction, semax completely prevented ischemia-induced ultrastructural changes of cardiomyocytes.

    In plain wordsIn rats with a heart attack, semax fully prevented ischemia-induced damage to the structure of heart muscle cells.

    Peptide
    Semax
    Outcome
    DecreaseIschemia-induced ultrastructural changes of cardiomyocytes
    Study

    ratn: not reported in source

    Acute myocardial infarction by left coronary artery occlusion
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    150 microg/kg · intraperitoneal · two doses, 15 min and 2 hours after coronary occlusionAs given in this study (rat).

    Source sentences

    Summary
    Semax (150 microg/kg), given i. p. 15 min and 2 hours after coronary occlusion, caused no effect on cardiac function, but completely prevented ischemia-induced ultrastructural changes of cardiomyocytes.
    1 context sentence
    Summary · context
    AMI was induced by left coronary artery occlusion, myocardial ischemic area averaged 30 % of left ventricle.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute myocardial infarction, semax blunted the increase in plasma nitrate concentrations seen in the AMI group.

    In plain wordsIn rats with a heart attack, semax reduced the rise in blood nitrates seen in the untreated heart attack group.

    Peptide
    Semax
    Outcome
    DecreasePlasma nitrate concentration
    Study

    ratn: not reported in source

    Acute myocardial infarction by left coronary artery occlusion
    Comparator
    AMI group
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    150 microg/kg · intraperitoneal · two doses, 15 min and 2 hours after coronary occlusionAs given in this study (rat).

    Source sentences

    Summary
    This protective effect was accompanied by the ability of peptide to blunt the increase in plasma concentrations of nitrates, observed in AMI group.
    1 context sentence
    Summary · context
    AMI was induced by left coronary artery occlusion, myocardial ischemic area averaged 30 % of left ventricle.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.